Skip to main content

Advertisement

Log in

Resolution of clinical and pathologic features of C1q nephropathy after rituximab therapy

  • Case Report
  • Published:
Clinical and Experimental Nephrology Aims and scope Submit manuscript

Abstract

C1q nephropathy is a rare idiopathic glomerulopathy characterized by mesangial deposition of immunoglobulin and complement with C1q dominance or co-dominance, and the absence of clinical and laboratory evidence of systemic lupus erythematosus. Its clinical course is unpredictable and the response to corticosteroid or cytotoxic treatment is variable. Here, we report two cases of C1q nephropathy, one in a child and one in an adult, both presenting with impaired renal function and massive proteinuria. Both patients failed to respond to immunosuppressive medications; however, rituximab, an anti-CD20 antibody, was effective in preserving renal function in one patient and eliminating the need for hemodialysis in the other. In one patient, histologic regression of abnormalities was documented over 3 years post-treatment. Both patients have remained off other immunosuppressive medication for a prolonged period with stable renal function. These cases are, to our knowledge, the first reported successful treatment of C1q nephropathy with rituximab.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Mii A, Shimizu A, Masuda Y, Fujita E, Aki K, Ishizaki M, et al. Current status and issues of C1q nephropathy. Clin Exp Nephrol. 2009;13:263–74.

    Article  CAS  PubMed  Google Scholar 

  2. Lau KK, Gaber LW, Delos Santos NM, Wyatt RJ. C1q nephropathy: features at presentation and outcome. Pediatr Nephrol. 2005;20:744–9.

    Article  PubMed  Google Scholar 

  3. Markowitz GS, Schwimmer JA, Stokes MB, Nasr S, Seigle RL, Valeri AM, et al. C1q nephropathy: a variant of focal segmental glomerulosclerosis. Kidney Int. 2003;64:1232–40.

    Article  CAS  PubMed  Google Scholar 

  4. Ahmed MS, Wong CF. Rituximab and nephrotic syndrome: a new therapeutic hope? Nephrol Dial Transpl. 2008;23:11–7.

    Article  Google Scholar 

  5. Yang T, Nast CC, Vo A, Jordan SC. Rapid remission of steroid and mycophenolate mofetil (MMF)-resistant minimal change nephrotic syndrome after rituximab therapy. Nephrol Dial Transpl. 2008;23:377–80.

    Article  Google Scholar 

  6. Sfikakis PP, Boletis JN, Lionaki S, Vigklis V, Fragiadaki KG, Iniotaki A, et al. Remission of proliferative lupus nephritis following B cell depletion therapy is preceded by down-regulation of the T cell costimulatory molecule CD40 ligand: an open-label trial. Arthritis Rheum. 2005;52:501–13.

    Article  CAS  PubMed  Google Scholar 

  7. Bitzan M, Ouahed JD, Krishnamoorthy P, Bernard C. Rituximab treatment of collapsing C1q glomerulopathy: clinical and histopathological evolution. Pediatr Nephrol. 2008;23:1355–61.

    Article  PubMed  Google Scholar 

  8. Jennette JC, Hipp CG. C1q nephropathy: a distinct pathologic entity usually causing nephrotic syndrome. Am J Kidney Dis. 1985;6:103–10.

    CAS  PubMed  Google Scholar 

  9. Iskandar SS, Browning MC, Lorentz WB. C1q nephropathy: a pediatric clinicopathologic study. Am J Kidney Dis. 1991;18:459–65.

    CAS  PubMed  Google Scholar 

  10. Vizjak A, Ferluga D, Rozic M, Hvala A, Lindic J, Levart TK, et al. Pathology, clinical presentations, and outcomes of C1q nephropathy. J Am Soc Nephrol. 2008;19:2237–44.

    Article  PubMed  Google Scholar 

  11. Hisano S, Fukuma Y, Segawa Y, Niimi K, Kaku Y, Hatae K, et al. Clinicopathologic correlation and outcome of C1q nephropathy. Clin J Am Soc Nephrol. 2008;3:1637–43.

    Article  PubMed  Google Scholar 

  12. Marcus R, Hagenbeek A. The therapeutic use of rituximab in non-Hodgkin’s lymphoma. Eur J Haematol Suppl. 2007;67:5–14.

    Article  CAS  PubMed  Google Scholar 

  13. Gilbert RD, Hulse E, Rigden S. Rituximab therapy for steroid dependent minimal change nephrotic syndrome. Pediatr Nephrol. 2006;21:1698–700.

    Article  PubMed  Google Scholar 

  14. Bagga A, Sinha A, Moudgil A. Rituximab in patients with the steroid-resistant nephrotic syndrome. N Engl J Med. 2007;356:2751–2.

    Article  CAS  PubMed  Google Scholar 

  15. Pescovitz MD, Book BK, Sidner RA. Resolution of recurrent focal segmental glomerulosclerosis proteinuria after rituximab treatment. N Engl J Med. 2006;354:1961–3.

    Article  CAS  PubMed  Google Scholar 

  16. Fernandez-Fresnedo G, Segarra A, González E, Alexandru S, Delgado R, Ramos N, et al. Trabajo de Enfermedades Glomerulares de la Sociedad Española de Nefrología (GLOSEN): rituximab treatment of adult patients with steroid-resistant focal segmental glomerulosclerosis. Clin J Am Soc Nephrol. 2009;4:1317–23.

    Article  CAS  PubMed  Google Scholar 

  17. Segarra A, Praga M, Ramos N, Polanco N, Cargol I, Gutierrez-Solis E, et al. Successful treatment of membranous glomerulonephritis with rituximab in calcineurin inhibitor-dependent patients. Clin J Am Soc Nephrol. 2009;4:1083–8.

    Article  CAS  PubMed  Google Scholar 

  18. Berger SP, Roos A, Daha MR. Complement and the kidney: what the nephrologists needs to know in 2006? Nephrol Dial Transpl. 2005;20:2613–9.

    Article  Google Scholar 

  19. Soares MP, Bach FH. C1q receptors and endothelial cell activation. J Lab Clin Med. 1999;133:520–2.

    Article  CAS  PubMed  Google Scholar 

  20. Uwatoko S, Aotsuka S, Okawa M, Egusa Y, Yokohari R, Aizawa C, et al. Characterization of C1q-binding IgG complexes in systemic lupus erythematosus. Clin Immunol Immunopathol. 1984;30:104–16.

    Article  CAS  PubMed  Google Scholar 

  21. Hauptrock B, Hess G. Rituximab in the treatment of non-Hodgkin’s lymphoma. Biologics. 2008;4:619–33.

    Google Scholar 

Download references

Acknowledgments

We would like to acknowledge the support of the International Society of Nephrology through its Renal Sister Center Program (All India Institute of Nephrology and Cedars-Sinai Medical Center).

Conflict of interest

Stanley C. Jordan, M.D. has a research grant from Genentech®, the manufacturer of rituximab to study its effects in kidney transplant patients. This grant did not conflict with this report. No other authors have disclosures to make regarding conflict of interest.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Stanley C. Jordan.

About this article

Cite this article

Sinha, A., Nast, C.C., Hristea, I. et al. Resolution of clinical and pathologic features of C1q nephropathy after rituximab therapy. Clin Exp Nephrol 15, 164–170 (2011). https://doi.org/10.1007/s10157-010-0377-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10157-010-0377-x

Keywords

Navigation